These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 33981141

  • 1. Management of Cough in Patients with Chronic Obstructive Pulmonary Disease: Results of the Multicenter Randomized Placebo-Controlled Clinical Trial.
    Avdeev SN, Vizel AA, Abrosimov VN, Zaicev AA, Ignatova GL, Khamitov RF, Mikhaylusova MP, Shapovalova JS, Pavlysh EF, Trofimov BI, Emelyanov AV, Martynenko TI, Martynenko VA, Kostina NE, Chizhov DA, Chizhova OY, Kuzubova NA, Makova EV, Makarova EV.
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1243-1253. PubMed ID: 33981141
    [Abstract] [Full Text] [Related]

  • 2. [Rengalin, a New Efficacious and Safe Antitussive Agent. Results of a Randomized, Comparative, Multicenter Clinical Trial in Patients with Acute Respiratory Tract Infections].
    Akopov AL, Aleksandrova EB, Il'kovich MM, Petrov DV, Trofimov VI.
    Antibiot Khimioter; 2015; 60(1-2):19-26. PubMed ID: 26168681
    [Abstract] [Full Text] [Related]

  • 3. [Rengalin, a novel drug for treatment of cough in children. Intermediate data on multicentre, comparative randomized clinical trial].
    Geppe NA, Kondyurina EG, Galustyan AN, Pak TE, Baltserovich NB, Zhiglinskaya OV, Kamaev AV, Lazareva SG, Laleko SL, Melnikova IM, Mikhalkova EV, Perminova OA, Sabitov AU, Spivakovsky YM.
    Antibiot Khimioter; 2014; 59(7-8):16-24. PubMed ID: 25975103
    [Abstract] [Full Text] [Related]

  • 4. Low-dose oral theophylline combined with inhaled corticosteroids for people with chronic obstructive pulmonary disease and high risk of exacerbations: a RCT.
    Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, Burns G, Chaudhuri R, Chrystyn H, Davies L, Soyza A, Gompertz S, Haughney J, Innes K, Kaniewska J, Lee A, Morice A, Norrie J, Sullivan A, Wilson A, Price D.
    Health Technol Assess; 2019 Jul; 23(37):1-146. PubMed ID: 31343402
    [Abstract] [Full Text] [Related]

  • 5. Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease.
    Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM.
    Int J Chron Obstruct Pulmon Dis; 2014 Jul; 9():715-21. PubMed ID: 25031533
    [Abstract] [Full Text] [Related]

  • 6. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM, Beier J, Candler H, Wittig T.
    Int J Chron Obstruct Pulmon Dis; 2016 Jul; 11():2877-2884. PubMed ID: 27920515
    [Abstract] [Full Text] [Related]

  • 7. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA, Pudi KK, Zvarich MT, Sanford L, Siederer SK, Crim C.
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 9. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Kew KM, Mavergames C, Walters JA.
    Cochrane Database Syst Rev; 2013 Oct 15; 2013(10):CD010177. PubMed ID: 24127118
    [Abstract] [Full Text] [Related]

  • 10. Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial.
    Rabe KF, Watz H, Baraldo S, Pedersen F, Biondini D, Bagul N, Hanauer G, Göhring UM, Purkayastha D, Román J, Alagappan VKT, Saetta M.
    Lancet Respir Med; 2018 Nov 15; 6(11):827-836. PubMed ID: 30224319
    [Abstract] [Full Text] [Related]

  • 11. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β2-Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double-Blind, Placebo-controlled Trial.
    Stolz D, Hirsch HH, Schilter D, Louis R, Rakic J, Boeck L, Papakonstantinou E, Schindler C, Grize L, Tamm M.
    Am J Respir Crit Care Med; 2018 May 01; 197(9):1136-1146. PubMed ID: 29266965
    [Abstract] [Full Text] [Related]

  • 12. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.
    Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, Hameleers N, Wouters EFM, Janssen DJA.
    JAMA Intern Med; 2020 Oct 01; 180(10):1306-1314. PubMed ID: 32804188
    [Abstract] [Full Text] [Related]

  • 13. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D, Papi A, Corradi M, Pavlišová I, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Vestbo J.
    Lancet; 2016 Sep 03; 388(10048):963-73. PubMed ID: 27598678
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
    Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF, ACCORD I study investigators.
    COPD; 2012 Apr 03; 9(2):90-101. PubMed ID: 22320148
    [Abstract] [Full Text] [Related]

  • 15. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
    Baumgartner RA, Hanania NA, Calhoun WJ, Sahn SA, Sciarappa K, Hanrahan JP.
    Clin Ther; 2007 Feb 03; 29(2):261-78. PubMed ID: 17472819
    [Abstract] [Full Text] [Related]

  • 16. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS).
    Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M.
    Respir Med; 2003 Jan 03; 97 Suppl A():S35-43. PubMed ID: 12564609
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.
    Rabe KF, Celli BR, Wechsler ME, Abdulai RM, Luo X, Boomsma MM, Staudinger H, Horowitz JE, Baras A, Ferreira MA, Ruddy MK, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, Goulaouic H.
    Lancet Respir Med; 2021 Nov 03; 9(11):1288-1298. PubMed ID: 34302758
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial.
    Hanania NA, Boota A, Kerwin E, Tomlinson L, Denis-Mize K.
    Drugs; 2009 Jun 18; 69(9):1205-16. PubMed ID: 19537837
    [Abstract] [Full Text] [Related]

  • 19. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T.
    Lancet Respir Med; 2018 May 18; 6(5):368-378. PubMed ID: 29477448
    [Abstract] [Full Text] [Related]

  • 20. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ, Keating GM.
    Treat Respir Med; 2004 May 18; 3(4):247-68. PubMed ID: 15350163
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.